Risk factors analysis for steroid-resistant acute graft versus host disease after haploidentical hematopoietic stem cell transplantation

Wenbin LIU; Yuqian SUN; Xiaohui ZHANG; Lanping XU; Yu WANG; Chenhua YAN; Huan CHEN; Yuhong CHEN; Wei HAN; Fengrong WANG; Jingzhi WANG; Kaiyan LIU; Xiaojun HUANG; Xiaodong MO

Return

Risk factors analysis for steroid-resistant acute graft versus host disease after haploidentical hematopoietic stem cell transplantation

VernacularTitle: 单倍型造血干细胞移植后糖皮质激素耐药急性移植物抗宿主病的危险因素分析
Author: Wenbin LIU ^{1
,

2} ; Yuqian SUN ¹ ; Xiaohui ZHANG ¹ ; Lanping XU ¹ ; Yu WANG ¹ ; Chenhua YAN ¹ ; Huan CHEN ¹ ; Yuhong CHEN ¹ ; Wei HAN ¹ ; Fengrong WANG ¹ ; Jingzhi WANG ¹ ; Kaiyan LIU ¹ ; Xiaojun HUANG ¹ ; Xiaodong MO ¹
Author Information

1. Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China
2. Department of Hematology, the First Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou 310006, China
Publication Type:Journal Article
Keywords: Hematopoietic stem cell transplantation; Graft versus host disease; Minnesota risk score; Steroid
From: Chinese Journal of Hematology 2020;41(2):106-111
CountryChina
Language:Chinese
Abstract: Objective:To analyze the risk factors of steroid resistant acute graft- versus-host disease (aGVHD) after haploidentical hematopoietic stem cell transplantation (haplo-HSCT) .
Methods:The clinical data of adult patients with acute myeloid leukemia (AML) /Myelodysplastic syndrome (MDS) who developed aGVHD after haplo-HSCT in Peking University Institute of Hematology from January 1st, 2010 to December 31st, 2012 were retrospectively reviewed.
Results:A total of 85 patients were enrolled in the study, including 55 males and 30 females, with a median age of 30 (19-67) years. After steroid therapy, there were 53 (62.4%) , 6 (7.1%) and 26 (30.6%) patients achieved complete remission (CR) , partial remission (PR) and non-remission (NR) , respectively. The CR rates of the grade Ⅰ/Ⅱ and Ⅲ/Ⅳ aGVHD by steroid therapy were 66.2% (51/77) vs 25.0% (2/8) (χ²=3.639, P=0.048) , respectively. The CR rates of the patients with aGVHD involving 1 target organ and 2 target organs were 77.4% (48/62) vs 21.7% (5/23) (χ²=22.157, P<0.001) . The CR rates of patients with standard risk (SR) and high risk (HR) Minnesota risk score was 67.5% (52/77) vs 12.5% (1/8) (χ²=7.153, P=0.004) . The mononuclear cells≥8.33×10⁸/kg and the HR Minnesota risk score were independent risk factors for steroid-resistant aGVHD in multivariate analysis. Between Minnesota risk score SR (77 cases) and HR (8 cases) groups, the OS rates at 22 months after transplantation were (90.3±3.8) %vs (75.0±15.3) % (χ²=2.831, P=0.092) . After steroid treatment for aGVHD, the OS rates at 22 months in the CR group (53 cases) and non-CR group (32 cases) were (95.2±3.4) %vs (78.6±7.9) % (χ²=5.287, P=0.021) respectively.
Conclusion:The Minnesota risk score and mononuclear cells count are effective tool for predicting steroid-resistant aGVHD after haplo-HSCT.